Abstract: Isolated HXHV virus having the following characteristics: (i) a DNA genome which is at least partially single-stranded, (ii) the said genome comprises one reading frame (ORF) encoding one protein or one polyprotein (iii) the said genome comprises a nucleotide sequence which exhibits, for any segment of at least 40 nucleotides belonging to the said sequence, at least 90% homology with SEQ ID NO: 1 or with its complementary sequence, nucleic material and peptide material and uses.

Abstract: The invention concerns a monoclonal antibody capable of binding with a wild type HBsAg antigen and with at least one, preferably at least two and advantageously more than two, mutated forms of the HBsAg antigen, the monoclonal antibody binding with the peptide sequence consisting of at least 6 adjacent amino acids in the 199-208 region of the HBsAg antigen, and advantageously binding with the peptide sequence formed by the 199-208 region of the HbsAg antigen.

Abstract: An oligopeptides comprising the following sequence Thr Gln Cys His Cys Gly Lys Cys (SEQ ID NO: 5) may be used as an antigenic compound capable of being recognized by anti-ovary antibodies and as an immunogenic compound capable of inducing the production of anti-ovary antibodies. In addition, the oligopeptides may be used to detect and/or quantify anti-ovary antibodies.

Abstract: The invention provides viral material and nucleotide fragments associated with multiple sclerosis and/or rheumatoid arthritis for use in methods of diagnosis, prophylaxis, and therapy.

Abstract: Viral material, in the isolated or purified state, in which the genome comprises a nucleotide sequence chosen from the group including sequences SEQ ID NO:46, SEQ ID NO:51, SEQ ID NO:52, SEQ ID NO:53 and SEQ ID NO:56, their complementary sequences and their equivalent sequences, in particular nucleotide sequences displaying, for any succession of 100 contiguous monomers, at least 50% and preferably at least 70% homology with the said sequences SEQ ID NO:46, SEQ ID NO:51, SEQ ID NO:52, SEQ ID NO:53 and SEQ ID NO:56, respectively, and their complementary sequences.

Abstract: Oligopeptides containing one of SEQ ID NOs: 1-5 may be used as antigenic compounds to recognize anti-ovary antibodies. The oligopeptides may also be used as immunogenic compounds to induce the production of anti-ovary antibodies.

Abstract: The invention provides viral material and nucleotide fragments associated with multiple sclerosis and/or rheumatoid arthritis for use in methods of diagnosis, prophylaxis, and therapy.

Abstract: Viral material, in the isolated or purified state, in which the genome comprises a nucleotide sequence chosen from the group including sequences SEQ ID NO:46, SEQ ID NO:51, SEQ ID NO:52, SEQ ID NO:53 and SEQ ID NO:56, their complementary sequences and their equivalent sequences, in particular nucleotide sequences displaying, for any succession of 100 contiguous monomers, at least 50% and preferably at least 70% homology with the said sequences SEQ ID NO:46, SEQ ID NO:51, SEQ ID NO:52, SEQ ID NO:53 and SEQ ID NO:56, respectively, and their complementary sequences.

Abstract: The invention concerns a polypeptide specifically reacting with the antibodies of patients suffering from multiple sclerosis (SEP) and whereof the peptide sequence comprises at least one sequence selected among SEQ ID No. 1 to SEQ ID NO: 19, and their equivalent sequences, and the use of this polypeptide in a reagent and a kit for detecting multiple sclerosis, an immunoreactive composition and in a method for fixing, in a biological sample, antibodies characteristic and/or specific of multiple sclerosis.

Abstract: The invention provides viral material and nucleotide fragments associated with multiple sclerosis and/or rheumatoid arthritis for use in methods of diagnosis, prophylaxis, and therapy.

Abstract: Viral material, in the isolated or purified state, in which the genome comprises a nucleotide sequence chosen from the group including sequences SEQ ID NO:46, SEQ ID NO:51, SEQ ID NO:52, SEQ ID NO:53 and SEQ ID NO:56, their complementary sequences and their equivalent sequences, in particular nucleotide sequences displaying, for any succession of 100 contiguous monomers, at least 50% and preferably at least 70% homology with the said sequences SEQ ID NO:46, SEQ ID NO:51, SEQ ID NO:52, SEQ ID NO:53 and SEQ ID NO:56, respectively, and their complementary sequences.

Abstract: Polypeptide able to react specifically with an antibody directed against the C33 antigen of hepatitis C virus, and that has a peptide sequence including all or part of the Asp-Gly-Ala-Lys-Phe-Ser-Ser-Arg-Leu-Gly-Ala-Ala-Gly-Ala SEQ ID NO: 1 sequence, or a sequence derived from this peptide sequence recognized by the antibody. This polypeptide has applications for detection of C33 antigen and anti-C33 antibodies.

Abstract: The invention relates to a polypeptide capable of reacting specifically with an anti-Toxoplasma gondii P30 protein antibody, and comprising a peptide sequence, in which any succession of 6 contiguous amino acids exhibits at most 67% homology with the peptide sequence of said P30 protein, identified by SEQ ID No.1, or comprising a sequence derived from said peptide sequence, and the applications of this polypeptide especially for detecting a Toxoplasma gondii infection, in a biological sample.